LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC (LUNAR-2)
LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Sponsor: NovoCure GmbH
A PHASE3 clinical study on Metastatic Non-small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by NovoCure GmbH and has accumulated 13 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE3
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE3
-
Sep 2025 — Oct 2025 [monthly]
Recruiting PHASE3
▶ Show 8 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Jul 2025 — Aug 2025 [monthly]
Recruiting PHASE3
-
May 2025 — Jul 2025 [monthly]
Recruiting PHASE3
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE3
-
Dec 2024 — Mar 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- NovoCure GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Afula, Israel , Alessandria, Italy , Annapolis, United States , Arnhem, Netherlands , Auburn, United States , Baden, Switzerland , Barcelona, Spain , Barrington, United States , Bergamo, Italy , Berlin, Germany and 75 more locations